Skip to main content
SpringerLink
Log in

Epidermal Growth Factor Receptor Inhibition in Cancer Therapy: Biology, Rationale and Preliminary Clinical Results

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

The epidermal growth factor receptor (EGFR), a growth factor receptor involved in the regulation of cellular differentiation and proliferation, is highly expressed by many tumor cells. In light of a relationship between overexpression of EGFR and clinically aggressive malignant disease, EGFR has emerged as a promising target for cancer therapy. In recent years, several molecular strategies have been explored to modulate either the EGFR itself, or the downstream signal beyond the cell surface receptor. One of the most promising current strategies involves the use of anti-EGFR monoclonal antibodies (mAbs), either alone or in combination with conventional cytotoxic modalities such as chemotherapy or radiotherapy. This review focuses primarily on recent progress in the development of anti-EGFR mAbs, and examines their potential in the treatment of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Cri Rev Oncol Hematol 19: 183–232, 1995

    Google Scholar 

  2. East R, Jr, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M, Berchuck A: Cell growth regulation in epithelial ovarian cancer. Cancer 71: 1597–1601, 1993

    Google Scholar 

  3. Ishikawa J, Maeda S, Umezu K, Sugiyama T, Kamidono S: Amplification and overexpression of the epidermal growth factor receptor gene in human renal-cell carcinoma. Int J Cancer 45: 1018–1021, 1990

    Google Scholar 

  4. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S, Nagura H: Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74: 795–804, 1994

    Google Scholar 

  5. Kim JW, Kim YT, Kim DK, Song CH, Lee JW: Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecologic Oncology 60: 283–287, 1996

    Google Scholar 

  6. Rikimaru K, Tadokoro K, Yamamoto T, Enomoto S, Tsuchida N: Gene amplification and overexpression of epidernal growth factor receptor in squamous cell carcinoma of the head and neck. Head & Neck 14: 8–13, 1992

    Google Scholar 

  7. Robertson KW, Reeves JR, Smith G, Keith WN, Ozanne BW, Cooke TG, Stanton PD: Quantitative estimation ofepidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res 56: 3823–3830, 1996

    Google Scholar 

  8. Sargent ER, Gomella LG, Belldegrun A, Linehan WM, Kasid A: Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. J Urol 142: 1364–1368, 1989

    Google Scholar 

  9. Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL: Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 46: 149–153, 1993

    Google Scholar 

  10. Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini ME, Cadoni G, Benedetti-Panici P, Paludetti G, Scambia G, Mancuso S: Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74: 1253–1257, 1996

    Google Scholar 

  11. Wikstrand CJ, Bigner DD: Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha. J Natl Cancer Inst 90: 799–801, 1998

    Google Scholar 

  12. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90: 824–832, 1998

    Google Scholar 

  13. Carpenter G, Cohen S: Epidennal growth factor. J Biol Chem 265: 7709–7712, 1990

    Google Scholar 

  14. van der Geer P, Hunter T, Lindberg RA: Receptor proteintyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10: 251–337, 1994

    Google Scholar 

  15. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203–212, 1990

    Google Scholar 

  16. Mendelsohn J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3: 2703–2707, 1997

    Google Scholar 

  17. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, McLeod C, Mendelsohn J: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidernal growth factor stimulated tyrosine protein kinase activity. J Biol Chem 259: 7755–7760, 1984

    Google Scholar 

  18. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1: 511–529, 1983

    Google Scholar 

  19. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J: Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 80: 1337–1341, 1983

    Google Scholar 

  20. Fan Z, Mendelsohn J, Masui H, Kumar R: Regulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies. J Biol Chem 268: 21073–21079, 1993

    Google Scholar 

  21. Sunada H, Magun BE, Mendelsohn J, MacLeod CL: Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 83: 3825–3829, 1986

    Google Scholar 

  22. Sunada H, Yu P, Peacock JS, Mendelsohn J: Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody. J Cell Physiol 142: 284–292, 1990

    Google Scholar 

  23. Fan Z, Lu Y, Wu X, Mendelsohn J: Antibody-induced epidernal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269: 27595–27602, 1994

    Google Scholar 

  24. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM: Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 37: 343–349, 1993

    Google Scholar 

  25. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1: 1311–1318, 1995

    Google Scholar 

  26. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB: Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 86: 4220–4224, 1989

    Google Scholar 

  27. Bos M, Mendelsohn J, Bowden C, Pfister D, Cooper MR, Cohen R, Burtness B, D'Andrea G, Waksal H, Norton L, Baselga J: Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors. Proc Am Soc Clin Oncol 15: A1381, 1996

    Google Scholar 

  28. Giorgio N, Zuklys K, Cooper M, Kissinger R, Waksal H: Pharmacokinetics in a phase I study of a chimerized monoclonalepidermal growth factor receptor (EGFr) antibody C225, as determined by surface plasmon resonance. Proc Am Assoc Cancer Res 37: A1230, 1996

    Google Scholar 

  29. Cooper MR, Cohen R, Anderson V, Falcey J, Waksal H: Pharmacokinetics of a chimerized monoclonal antibody (C225) against the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 17: A834, 1998

    Google Scholar 

  30. Yang XD, Jia XC, Corvalan J, Wang P, Davis CG, Jakobovits A: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59: 1236–1243, 1999

    Google Scholar 

  31. Falcey J, Pfister D, Cohen R, Cooper M, Bowden C, Burtness B, Mendelsohn J, Waksal H: A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients (pts) with head and neck or lung carcinomas. Proc Am Soc Clin Oncol 16: A1364, 1997

    Google Scholar 

  32. Perez-Soler R, Shin DM, Donato R, Radinsky R, Khuri F, Glisson BS, Shin H, Matsumoto T, Lawhorn K, Waksal H, Hong WK, Mendelsohn J: Tumor studies in patients with head & neck cancer treated with humanized anti-epidermal growth factor (EGFR) monoclonal antibody C225 in combination with cisplatin. Proc Am Soc Clin Oncol 17: A1514, 1998

    Google Scholar 

  33. Slovin SF, Kelly WK, Cohen R, Cooper M, Malone T, Weingard K, Waksal H, Falcey J, Mendelsohn J, Scher HI: Epidermal growth factor receptor (EGFr) monoclonal antibody (MoAb) C225 and doxorubicin (DOG) in androgenindependent (AI) prostate cancer (PC): results of a phase Ib/IIa study. Proc Am Soc Clin Oncol 16: A1108, 1997

    Google Scholar 

  34. Ennis BW, Valverius EM, Bates SE, Lippman ME, Bellot F, Kris R, Schlessinger J, Masui H, Goldenberg A, Mendelsohn J, et al: Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol 3: 1830–1838, 1989

    Google Scholar 

  35. Karnes W, Jr., Walsh JH, Wu SV, Kim RS, Martin MG, Wong HC, Mendelsohn J, Park JG, Cuttitta F: Autonomous proliferation of colon cancer cells that coexpress transforming growth factor alpha and its receptor. Variable effects of receptor-blocking antibody. Gastroenterology 102: 474–485, 1992

    Google Scholar 

  36. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95: 1897–1905, 1995

    Google Scholar 

  37. Atlas I, Mendelsohn J, Baselga J, Fair WR, Masui H, Kumar R: Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. Cancer Res 52: 3335–3339, 1992

    Google Scholar 

  38. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J: Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 56: 3666–3669, 1996

    Google Scholar 

  39. Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A, Mendelsohn J: Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12: 1397–1403, 1996

    Google Scholar 

  40. Huang S-M, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1934–1940, 1999

    Google Scholar 

  41. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44: 1002–1007, 1984

    Google Scholar 

  42. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM et al.: Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 83: 97–104, 1991

    Google Scholar 

  43. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelian growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151: 1523–1530, 1997

    Google Scholar 

  44. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD, Fidler IJ: Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1: 19–31, 1995

    Google Scholar 

  45. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CPN: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5: 257–264, 1999

    Google Scholar 

  46. Khazaie K, Schirrmacher V, Lichtner RB: EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 12: 255–274, 1993

    Google Scholar 

  47. Dejong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw A, Sluiter WJ, Peeters P, Slooff M, Devries E: Clinical relevance of transforming growth factor alpha epidermal growth factor receptor, p53, and ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 28: 971–979, 1998

    Google Scholar 

  48. Damstrup L, Voldborg BR, Spangthomsen M, Brunner N, Poulsen HS: In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Br J Cancer 78: 631–640, 1998

    Google Scholar 

  49. Chen LL, Narayanan R, Hibbs MS, Benn PA, Clawson ML, Lu G, Rhim JS, Greenberg B, Mendelsohn J: Altered epidermal growth factor signal transduction in activated Ha-ras transformed human keratinocytes. Biochem Biophys Res Commun 193: 167–174, 1993

    Google Scholar 

  50. Zolfaghari A, Djakiew D: Inhibition of chemoimigration of a human prostatic carcinoma cell (TSU-pr1) line by inhibition of epidermal growth factor receptor function. Prostate 28: 232–238, 1996

    Google Scholar 

  51. Christen RD, Hom DK, Porter DC, Andrews PA, MacLeod CL, Hafstrom L, Howell SB: Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest 86: 1632–1640, 1990

    Google Scholar 

  52. Christen RD, Isonishi S, Jones JA, Jekunen AP, Hom DK, Kroning R, Gately DP, Thiebaut FB, Los G, Howell SB: Signaling and drug sensitivity. Cancer Metastasis Rev 13: 175–189, 1994

    Google Scholar 

  53. Kroning R, Jones JA, Hom DK, Chuang CC, Sanga R, Los G, Howell SB, Christen RD: Enhancement of drug sensitivity of human malignancies by epidermal growth factor. Br J Cancer 72: 615–619, 1995

    Google Scholar 

  54. Mendelsohn J, Fan Z: Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 89: 341–343, 1997

    Google Scholar 

  55. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller W, Jr, Mendelsohn J: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85: 1327–1333, 1993

    Google Scholar 

  56. Fan Z, Baselga J, Masui H, Mendelsohn J: Antitumor effect of anti-epiderma growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53: 4637–4642, 1993

    Google Scholar 

  57. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80: 1605–1611, 1988

    Google Scholar 

  58. Kim YB, Perrotte P, Matsumoto T, Tsan R, Dinney CPN, Radinsky R: Immunochemotherapy of human transitional cell carcinoma (TCC) with anti-EGF-R monoclonal antibody (Mab) C225 and the anti-cancer drugs, taxol and cisplatinum. Proc Am Assoc Cancer Res 39: 64, 1998

    Google Scholar 

  59. Ciardiello FRB, Damiano V, De Lorenzo S, Pepe S, de Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5: 909–916, 1999

    Google Scholar 

  60. Mendelsohn J, Shin DM, Donato N, Khuri F, Radinsky R, Glisson BS, Shia HJ, Metz E, Pfister D, Perez-Soler R, Lawhorn K, Matsumoto T, Gunnett K, Falcey J, Waksal H, Hory WK: A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients with recurrent head and neck squamous cell carcinoma (SCC). Proc Am Soc Clin Oncol 18: A1502, 1999

    Google Scholar 

  61. Fowler JF, Lindstrom MJ: Loss of local control with prolongation is radiotherapy. Int J Radiat Oncol Biol Phys 23: 457–467, 1992

    Google Scholar 

  62. Harari PM, Kinsella TJ: Advances in radiation therapy for head and neck cancer. Curr Opin Oncol 7: 248–254, 1995

    Google Scholar 

  63. McGinn CJ, Harari PM, Fowler JF, Ford CN, Pyle GM, Kinsella TJ: Dose intensification in curative head and neck cancer radiotherapy-linear quadratic analysis and preliminary assessment of clinical results. Int J Radiat Oncol Biol Phys 27: 363–369, 1993

    Google Scholar 

  64. Schmidt-Ullrich RK, Valerie KC, Chan W, McWilliams D: Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int J Radiat Oncol Biol Phys 29: 813–819, 1994

    Google Scholar 

  65. Kavanagh BD, Lin PS, Chen P, Schmidt-Ullrich RK: Radiation-induced enhanced proliferation of human squamous cancer cells in vitro: a release from inhibition by epidermal growth factor. Clin Cancer Res 1: 1557–1562, 1995

    Google Scholar 

  66. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, Contessa JN, Rorrer WK, Chen PB: Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15: 1191–1197, 1997

    Google Scholar 

  67. Bonner JA, Maihle NJ, Folven BR, Christianson TJ, Spain K: The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys 29: 243–247, 1994

    Google Scholar 

  68. Howard SP, Groch KM, Lindstrom MJ, Messing EM, Gould MN: Proliferation-independent growth factor modulation of the radiation sensitivity of human prostate cells. Radiat Res 143: 229–233, 1995

    Google Scholar 

  69. Contessa JN, Reardon DB, Todd D, Dent P, Mikkelsen RB, Valerie K, Bowers GD, Schmidt-Ullrich RK: The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clin Cancer Res 5: 405–411, 1999

    Google Scholar 

  70. Balaban N, Moni J, Shannon M, Dang L, Murphy E, Goldkorn T: The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta 1314: 147–156, 1996

    Google Scholar 

  71. Huang S-M, Harari PM: Effects of anti-epidermal growth factor receptor monoclonal antibody 225 (M225) on proliferation, apoptosis and radiosensitivity in human squamous cell carcinomas of the head and neck. Proc Am Assoc Cancer Res 39: 64, 1998

    Google Scholar 

  72. Huang S-M, Harari PM: Modulation of radiation response in squamous cell carcinomas of the head and neck following EGFR blockade with anti-EGFR monoclonal antibody C225. Proc Am Assoc Cancer Res 40: 421, 1999

    Google Scholar 

  73. Saleh M, Buchsbaum D, Meredith R, Lalisan DJ, Wheeler R: In vitro and in vivo evaluation of the cytotoxicity of radiation combined with chemeric monoclonal antibody to the epidermal growth factor receptor. Proc Am Assoc Cancer Res 37: 612, 1996

    Google Scholar 

  74. Raben D, Buchsbaum DJ, Gillespie Y, Randall S, Saleh M, Waksal H: Treatment of human intracranial gloomas with chimeric monoclonal antibody against the epidermal growth factor receptor increases survival of nude mice when treated concurrently with irradiation. Proc Am Assoc Cancer Res 40: 184, 1999

    Google Scholar 

  75. Kwok TT, Sutherland RM: Cell cycle dependence of epidermal growth factor induced radiosensitization. Int J Radiat Oncol Biol Phys 22: 525–527, 1992

    Google Scholar 

  76. Laderoute KR, Ausserer WA, Knapp AM, Grant TD, Sutherland RM: Epidermal growth factor modifies cell cycle control in A431 human squamous carcinoma cells damaged by ionizing radiation. Cancer Res 54: 1407–1411, 1994

    Google Scholar 

  77. Wollman R, Yahalom J, Maxy R, Pinto J, Fuks Z: Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys 30: 91–98, 1994

    Google Scholar 

  78. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R: Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 273: 1568–1573, 1998

    Google Scholar 

  79. Ciardiello F, Tortora G: Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. Clin Cancer Res 4: 821–828, 1998

    Google Scholar 

  80. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR, Tortora G: Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 88: 1770–1776, 1996

    Google Scholar 

  81. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, Pepe S, Bianco AR, Agrawal S, Mendelsohn J, Tortora G: Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. J Natl Cancer Inst 90: 1087–1094, 1998

    Google Scholar 

  82. McLeod HL, Brunton VG, Eckardt N, Lear MJ, Robins DJ, Workman P, Graham MA: In vivo pharmacology and antitumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. Br J Cancer 74: 1714–1718, 1996

    Google Scholar 

  83. Dinney CP, Parker C, Dong Z, Fan D, Eve BY, Bucana C, Radinsky R: Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin Cancer Res 3: 161–168, 1997

    Google Scholar 

  84. Levitzki A, Gazit A: Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782–1788, 1995

    Google Scholar 

  85. Modjtahedi H, Affleck K, Stubberfield C, Dean C: Egfr blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptogis in the human squamous cell carcinoma hn5. Int J Oncol 13: 335–342, 1998

    Google Scholar 

  86. Karnes W, Jr, Weller SG, Adjei PN, Kottke TJ, Glenn KS, Gores GJ, Kaufmann SH: Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology 114: 930–939, 1998

    Google Scholar 

  87. Normanno N, Selvam MP, Bianco C, Damiano V, de Angelis E, Grassi M, Magliulo G, Tortora G, Salomon DS, Ciardiello F: Amphiregulin anti-sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line. Int J Cancer 62: 762–766, 1995

    Google Scholar 

  88. Ciardiello F, Bianco C, Normanno N, Baldassarre G, Pepe S, Tortora G, Bianco AR, Salomon DS: Infection with a transforming growth factor alpha anti-sense retroviral expression vector reduces the in vitro growth and transformation of a human colon cancer cell line. Int J Cancer 54: 952–958, 1993

    Google Scholar 

  89. Ciardiello F, Tortora G, Bianco C, Selvam MP, Basolo F, Fontanini G, Pacifico F, Normanno N, Brandt R, Persico MG: Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides.Oncogene 9: 291–298, 1994

    Google Scholar 

  90. Normanno N, Bianco C, Damiano V, de Angelis E, Selvam MP, Grassi M, Magliulo G, Tortora G, Bianco AR, Mendelsohn J, Salomon DS, Ciardiello F: Growth inhibition of human colon carcinoma cells by combinations of antiepidermal growth factor-related growth factor antisense oligonucleotides. Clin Cancer Res 2: 601–609, 1996

    Google Scholar 

  91. Ezekiel MP, Robert RF, Meredith RF, Spencer SA, Newsome J, Khazaeli MB, Peters GE, Saleh AF, LoBuglio AF, Waksal H: Phase I study of anti-epidermal growth factor receptor (EGFR) antibody C225 in combination with irradiation in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 17: A1522, 1998

    Google Scholar 

  92. Schnurch HG, Stegmuller M, Vering A, Beckmann MW, Bender HG: Growth inhibition of xenotransplanted human carcinomas by a monoclonal antibody directed against the epidermal growth factor receptor. Bur J Cancer 4: 491–496, 1994

    Google Scholar 

  93. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, Goldstein NI: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother 19: 419–427, 1996

    Google Scholar 

  94. Teramoto T, Onda M, Tokunaga A, Asano G: Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer. Cancer 77: 1639–1645, 1996

    Google Scholar 

  95. Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ: Mousehuman chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenograRs in nude mice. Clin Cancer Res 4: 2957–2966, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, USA

    Shyh-Min Huang & Paul M. Harari

Authors
  1. Shyh-Min Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul M. Harari
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, SM., Harari, P.M. Epidermal Growth Factor Receptor Inhibition in Cancer Therapy: Biology, Rationale and Preliminary Clinical Results. Invest New Drugs 17, 259–269 (1999). https://doi.org/10.1023/A:1006384521198

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006384521198

Search

Navigation